Ireland
--:--IST
Recruiting Not applicable

Ozone Gel Versus Chlorohexidine Gel as an Adjunct to Non-Surgical Treatment of Stage II Periodontitis Grade B Among Smokers Patients

NCT07923708 · tracked via the Priya Life Science Egypt tracker
Phase
Not applicable
Started
2026-09-01
Last updated
2026-11-06

Condition(s) studied

Ozone GelChlorohexidine GelNon-Surgical TreatmentStage II PeriodontitisSmokers

Investigational drug(s) / intervention(s)

Conventional scaling and root planingConventional scaling and root planing in addition to chlorhexidine gelConventional scaling and root planing in addition to ozone gel

Conventional scaling and root planing: Participants will receive conventional scaling and root planing only.

Conventional scaling and root planing in addition to chlorhexidine gel: Participants will receive conventional scaling and root planing in addition to chlorhexidine gel application according to the manufacturer's instructions for subgingival delivery.

Conventional scaling and root planing in addition to ozone gel: Participants will receive conventional scaling and root planing in addition to ozone gel application according to the manufacturer's instructions for subgingival delivery.

Study summary

The aim of the present study is to evaluate and compare the clinical and biochemical outcomes of Ozoral® and High Cure® (chlorhexidine gel) as adjuncts to non-surgical periodontal therapy in smoker patients with Stage II Grade B periodontitis, using non-smoker patients with the same diagnosis as a comparative control group.

Eligibility

Sex
ALL
Min age
25 Years
Max age
45 Years
Healthy volunteers
No
Inclusion Criteria: * Male and female patients aged 25-45 years * Diagnosed with Stage II Grade B periodontitis * Clinical attachment loss of 3-4 mm * Radiographic bone loss confined to the coronal third of the root * Either smokers or non-smokers Exclusion Criteria: * Systemic diseases affecting periodontal health * Pregnancy or lactating female * Periodontal therapy within the last 6 months * Use of antibiotics or anti-inflammatory medication during the last

Primary outcome measure(s)

  • Change in gingival crevicular fluid tumor necrosis factor-alpha level — 6 months after treatment
    Change from baseline in gingival crevicular fluid tumor necrosis factor-alpha (TNF-α) level will be measured using enzyme-linked immunosorbent assay (ELISA) at baseline, 15 days, and 6 months after treatment..

Trial sites (1)

FacilityCityRegionStatus
October 6 University Cairo Egypt Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07923708 on ClinicalTrials.gov ↗ ← All trials in Egypt